High-intensity and cycled phototherapy for newborn jaundice
Official title: Neonatal Hyperbilirubinemia - Phototherapeutic Treatment Strategies
Run by Regionshospital Nordjylland · NCT06702241 · Data updated 2026-11-12
This test compares higher-intensity and intermittent (cycled) phototherapy to standard continuous light to see which lowers bilirubin faster in newborns born at or after 33 weeks with non-hemolytic jaundice.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 1 Day to 14 Days |
| Sex | All |
| Enrollment | 116 (estimated) |
| Sponsor | Regionshospital Nordjylland Government |
| Locations | 2 sites (Aalborg and 1 other locations) |
| Status | Recruiting |
| Started | January 14, 2025 |
| Main results expected | November 1, 2027 |
| Study ends | November 1, 2029 |
| Registry record updated | November 20, 2025 |
| Trial ID | NCT06702241 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Newborns born at ≥33+0 weeks, weighing ≥1800 g, with serum bilirubin above the national treatment threshold and without signs of hemolysis or rapidly rising bilirubin are eligible.
✕Probably not a fit
Infants with jaundice within the first 24 hours of life, rapidly rising bilirubin suggestive of hemolysis, or those needing exchange transfusion or multi-sided intensive therapy are unlikely to benefit from the interventions tested here.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized multicenter trial will enroll 116 newborns (≥33+0 weeks gestation, ≥1800 g) with non-hemolytic hyperbilirubinemia above Danish treatment thresholds. All infants receive 12 hours of combined overhead phototherapy plus a biliblanket, with overhead irradiance set to 40, 55, or 70 µW/cm²/nm; the 70 µW/cm²/nm arm is split into continuous and cycled (intermittent) treatment, creating four groups. The trial is powered to compare bilirubin response across irradiance levels to define an upper effective limit and to compare cycled versus continuous delivery. Infants with rapidly rising bilirubin or other indications for immediate intensified therapy (multi-sided lights, exchange transfusion, or immunoglobulin) are excluded.
Why it matters
Potential benefit: If successful, the results could identify an optimal phototherapy dose and show whether intermittent treatment is as effective as continuous light, potentially shortening treatment or improving comfort.
How similar studies have gone: Smaller prior studies suggest cycled phototherapy can be as effective as continuous treatment, but evidence on benefits of very high irradiance levels remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Hyperbilirubinemia with a total serum bilirubin level above the limit of necessary treatment according to the Danish Pediatric Society's guidelines * Birth weight \>1800g * Gestational age \>33+0 Exclusion Criteria: * Hyperbilirubinemia within the first 24 hours of life * Rapidly increasing serum levels of bilirubnemia indicating pathology or hemolysis
Where it's running
-
Aalborg University Hospital, The Neonatal Department
Aalborg, Denmark Recruiting -
The North Denmark Regional Hospital, The Pediatric Department
Hjørring, Denmark Recruiting
Study contacts
- Study coordinator: Emil L Oehrstroem, MD
- Email: e.oehrstroem@rn.dk
- Phone: +45 24830384
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Kangaroo Care by Mother or Nurse to Reduce Pain During Phototherapy in Newborns
This study tests whether mother-administered or nurse-administered kangaroo care during a heel-stick procedure reduces pain in newborns with hyperbilirubinemia, compared with standard care.
-
Foot reflexology and massage for newborns receiving light therapy
This trial tests whether foot reflexology or body massage, added to standard phototherapy, can help lower bilirubin levels and improve stability in newborns with indirect hyperbilirubinemia.
-
Breath carbon monoxide measurement to help manage newborn jaundice.
This project tests whether measuring end-tidal carbon monoxide from a newborn's breath in the first three days can help guide jaundice care for full-term babies.
-
Using exhaled carbon monoxide to guide modified care for newborn hemolysis causing severe jaundice
This trial will test whether adding a bedside exhaled-carbon monoxide (ETCOc) measurement to a modified diagnosis and treatment plan can help prevent brain damage in newborns with severe hyperbilirubinemia.
-
Determining safe levels to stop phototherapy for newborn jaundice
This study is testing if stopping light treatment for jaundice in newborns at a lower level is safer and helps prevent a return of high bilirubin levels compared to stopping at a higher level.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.